Intuitive Surgical stock (US46120E6023): Robotic surgery leader digests post-earnings pullback

Intuitive Surgical shares are consolidating after the latest quarterly results and updated procedure trends. What is driving the move in the robotic surgery pioneer – and what should US investors know about the business model behind the da Vinci platform?

Intuitive Surgical, Inc. stock has been in focus among US healthcare investors after the latest quarterly update on its da Vinci robotic surgery platform and procedure volumes, which was followed by a noticeable share price pullback compared with earlier in the year, according to data from Nasdaq as of 05/22/2026 and recent earnings coverage by major financial media such as Reuters as of 04/17/2025.

The company continues to report growing global procedure adoption and an expanding installed base of systems, even as investors reassess valuation after the most recent earnings release and commentary on near-term capital spending by hospitals, according to company filings and coverage by Intuitive Surgical Investor Relations as of 04/18/2025.

As of: 26.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intuitive Surgical
• Sector/industry: Medical technology / surgical robotics
• Headquarters/country: Sunnyvale, United States
• Core markets: Minimally invasive surgery in the US, Europe and Asia
• Key revenue drivers: da Vinci systems, instruments, accessories and services
• Home exchange/listing venue: Nasdaq (ticker: ISRG)
• Trading currency: US dollar (USD)

Intuitive Surgical, Inc.: core business model

Intuitive Surgical focuses on robotic-assisted minimally invasive surgery, with the da Vinci platform at the center of its business model, according to company descriptions on its corporate site and filings with the US Securities and Exchange Commission, including the latest Form 10-K as of 02/06/2025 published via Intuitive Surgical Investor Relations as of 02/06/2025.

The company generates revenue through a mix of capital sales of robotic systems, recurring sales of instruments and accessories used in each procedure, and services and maintenance contracts with hospitals and surgical centers, as outlined in its annual report for the fiscal year 2024 released in early 2025 via Intuitive Surgical Investor Relations as of 01/25/2025.

A key feature of the business model is that installed systems tend to drive high-margin recurring revenue over time due to ongoing demand for specialized instruments and accessories, meaning that each new system placement can translate into a long-term stream of procedural revenue, according to detailed segment disclosures in the 2024 Form 10-K as of 02/06/2025 provided by Intuitive Surgical Investor Relations as of 02/06/2025.

Management highlights that the company invests heavily in surgeon training, clinical evidence and digital tools to support adoption of robotic-assisted surgery, which aims to improve patient outcomes and hospital efficiency, based on comments in the 2024 annual report and presentations at recent investor conferences summarized by MarketBeat as of 05/22/2026.

The company’s revenue base is diversified across procedures in urology, gynecology, general surgery and thoracic surgery, with particular emphasis on minimally invasive procedures that can be standardized and scaled globally, as described in its 2024 annual report and related investor presentations hosted in early 2025 via Intuitive Surgical Investor Relations as of 03/12/2025.

Main revenue and product drivers for Intuitive Surgical, Inc.

According to the company’s full-year 2024 results, Intuitive Surgical reported total revenue growth driven primarily by higher procedure volumes and an increase in its installed base of da Vinci systems, as disclosed in a press release dated 01/25/2025 on Intuitive Surgical Investor Relations as of 01/25/2025.

For the fourth quarter of 2024, the company reported revenue of approximately USD 2.2 billion, representing double-digit percentage growth versus the prior-year quarter, driven by a high single-digit to low double-digit increase in global procedures, according to the same earnings release dated 01/25/2025 from Intuitive Surgical Investor Relations as of 01/25/2025.

Instruments and accessories revenue remains the largest component of the top line, reflecting recurring demand tied to the number of surgical procedures performed with da Vinci systems, as detailed in segment disclosures within the 2024 Form 10-K filed with the SEC and made available via Intuitive Surgical Investor Relations as of 02/06/2025.

System revenue can be more cyclical because it depends on hospitals’ capital spending plans, but each new system placed tends to support future growth in instruments, accessories and service revenue, according to management commentary in the fourth-quarter 2024 earnings call transcript published on 01/25/2025 by Intuitive Surgical Investor Relations as of 01/25/2025.

The company also generates income from its Ion endoluminal system for minimally invasive biopsies in the lung, which is highlighted as a growing contributor within the broader portfolio of products, as described in product overviews and management commentary on growth opportunities in lung procedures available on Intuitive Surgical corporate site as of 03/15/2025.

Management reports that operating margins are influenced by the mix of system placements versus recurring revenue, as well as ongoing investments in research and development and global commercial expansion, according to the 2024 annual report and fourth-quarter earnings presentation released through Intuitive Surgical Investor Relations as of 01/25/2025.

Conclusion

Intuitive Surgical, Inc. remains one of the best-known names in robotic-assisted minimally invasive surgery, with a business model built on a growing installed base of da Vinci systems and recurring revenue from procedures and services, according to its 2024 annual report and recent earnings releases shared via Intuitive Surgical Investor Relations in early 2025.

Recent quarterly results showed continued growth in global procedure volumes and revenue, while the share price has consolidated from earlier highs as investors weigh capital spending trends and valuation relative to growth expectations, based on share price data from MarketBeat as of 05/22/2026 and accompanying analysis of year-to-date performance.

For US investors, the stock offers exposure to a leading medical technology company with a significant presence in the domestic hospital market and an expanding international footprint, but it also comes with the usual sector-specific risks such as regulatory changes, competitive dynamics and potential shifts in hospital investment priorities, as highlighted in the company’s risk disclosures in the 2024 Form 10-K filed with the SEC and referenced on Intuitive Surgical Investor Relations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.